Pathological current of climacterium leads to significant decrease in quality of life of women. Hormone therapy has a number of contra-indications. With the purpose of optimization of treatment of patients with a climacteric syndrome search of new and more perfect approaches to therapy of climacteric frustration is necessary. Melatonin production in a human body decreases with the years and its production in old age makes only half from its level. Age decrease of melatonin synthesis leads to progressive decrease of woman fertility. In this connection the research of a level of melatonin in women with a climacteric syndrome depending on current of disease was carried out. The opportunity to use the Melaxen in treatment of symptoms of pathological climacterium both in the form of monotherapy, and in combination with replacement hormone therapy was estimated. The greatest efficiency of application of Melaxen in combination with hormone replacement therapy has been established.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
School of Pharmacy, Chapman University, Irvine, CA, USA.
Background: Although novel treatments for Alzheimer's disease (AD) have begun to show modest therapeutic effects, agents that target hallmark AD pathology and offer neuroprotection are desired. Erythropoietin (EPO) is a glycoprotein hormone with neuroprotective effects but is faced with challenges including limited brain uptake and increased hematopoietic side effects with long-term dosing. Therefore, EPO has been modified and bound to a chimeric transferrin receptor monoclonal antibody (cTfRMAb); the latter shuttles EPO past the blood-brain barrier (BBB) into brain parenchyma and reduces its plasma exposure and potential for side effects.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada.
Background: Alzheimer's disease (AD) is a neurodegenerative disorder primarily associated with aging, but manifests as a complex interplay of multiple factors. Decline in sex-hormones, particularly 17-beta estradiol, is linked to the aging process. The risk for onset of AD significantly increases with aging and loss of estradiol.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Women account for almost two-thirds of Alzheimer's disease (AD) cases, yet evidence significantly less clinical benefit from recently deployed amyloid-lowering therapies. To close this disparity gap, there is an urgent need to identify biological drivers of sex differences in the manifestation and clinical response to AD therapeutics. A recent review of multi-omic studies of AD reported >75% of studies showed female-specific changes at the molecular level (vs.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Odessa National Maritime University, Odessa, Ukraine.
Background: Alzheimer's disease can cause sleep disturbances in humans, which can worsen other symptoms of the disease.
Method: In our study, we examined the sleep patterns of 23 patients with Alzheimer's disease, aged 65-74 years (20 women and 3 men), over 4 months. All patients reported experiencing poor sleep, including difficulty sleeping in the ward, frequent awakenings during the night, early morning awakenings, and daytime sleepiness.
A Combination of Fruit Rind and Seed Extracts Enhances Sexual Function in Aging Males in a Randomized, Double-blind, Placebo-controlled Study.
Int J Med Sci
January 2025
Department of General Medicine, Yalamanchi Hospitals and Research Centre, Vijayawada-520002, Andhra Pradesh, India.
LN18178 is a standardized, synergistic combination of fruit rind and seed extracts, which has been reported to increase serum testosterone levels in young and aging males. The present 84-day randomized, double-blind, placebo-controlled study assessed the efficacy of LN18178 on the sexual function of aging male volunteers (age: 40-70 years; serum total testosterone: ≥ 300 ng/dL). The subjects with mild to moderate erectile dysfunction [5-item version of the International Index of Erectile Function (IIEF-5) scores 17-25] and low sexual desire (score < 3 on items 11 and 12 of IIEF) participated in this investigation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!